Global Blood reports Phase IIa data for voxelotor in sickle cell disease

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported interim data from 11 evaluable patients with sickle cell disease in part B of the open-label, U.S. Phase IIa HOPE-KIDS 1 (GBT440-007) trial showing

Read the full 309 word article

User Sign In